Rationale for Extended Adjuvant Letrozole after Five Years of Tamoxifen in Postmenopausal Oestrogen Receptor–Positive Women with Early-Stage Breast Cancer
Excerpt
Hormonal therapy has been an integral component of the adjuvant strategy for women with hormone receptor–positive breast cancer for decades [...]
Share and Cite
McArthur, H.L.; Kennecke, H.F. Rationale for Extended Adjuvant Letrozole after Five Years of Tamoxifen in Postmenopausal Oestrogen Receptor–Positive Women with Early-Stage Breast Cancer. Curr. Oncol. 2005, 12, 78-82. https://doi.org/10.3390/curroncol12030003
McArthur HL, Kennecke HF. Rationale for Extended Adjuvant Letrozole after Five Years of Tamoxifen in Postmenopausal Oestrogen Receptor–Positive Women with Early-Stage Breast Cancer. Current Oncology. 2005; 12(3):78-82. https://doi.org/10.3390/curroncol12030003
Chicago/Turabian StyleMcArthur, H. L., and H. F. Kennecke. 2005. "Rationale for Extended Adjuvant Letrozole after Five Years of Tamoxifen in Postmenopausal Oestrogen Receptor–Positive Women with Early-Stage Breast Cancer" Current Oncology 12, no. 3: 78-82. https://doi.org/10.3390/curroncol12030003
